

Boots is set to make history by becoming the first major UK high street pharmacy to offer private medical cannabis prescriptions, in a landmark move that could change how patients access cannabis-based medicines across the country.
The pharmacy giant has launched a new specialist service, called SureLeaf, through its Boots Online Doctor platform. The service will give eligible patients aged 25 and over access to medical cannabis treatment for certain long-term health conditions, including chronic pain, generalised anxiety disorder and insomnia.
The announcement marks a significant development for the UK's growing medical cannabis industry, which has largely been served by specialist private clinics since cannabis-based medicines were legalised for specialist prescribing in 2018.
Boots says patients will initially complete an online assessment to establish whether they may be suitable for treatment.
Their application will then be reviewed by a clinical team before eligible patients progress to a video consultation with a consultant who is listed on the General Medical Council's Specialist Register.
Importantly, receiving a prescription will not be automatic. Patients must demonstrate that they have previously tried conventional treatments without achieving adequate symptom relief.
Any proposed prescription will also undergo an independent review by a multidisciplinary clinical team, including a second consultant, before treatment can begin.
Boots says patients will receive continued clinical support throughout their treatment. This will include an initial review after 28 days, followed by further assessments at least every three months.
The company says the monitoring process will assess factors such as pain, sleep, anxiety, mood and overall quality of life.
The SureLeaf service will cover a range of conditions, with a particular focus on patients who have not experienced sufficient relief from conventional treatments.
Eligible conditions include:
Other eligible conditions include trigeminal neuralgia, phantom limb pain and chronic abdominal or pancreatic pain.
However, Boots has stressed that medical cannabis is not suitable for everyone and that every patient will need an individual clinical assessment.
Medical cannabis became legal for specialist prescription in the UK in November 2018, following changes to the law prompted by high-profile cases involving children with severe epilepsy.
Despite the legal change, access to cannabis-based medicinal products through the NHS has remained extremely limited.
NHS prescriptions are generally restricted to specific circumstances involving rare forms of epilepsy, chemotherapy-related nausea and vomiting, and muscle spasticity associated with multiple sclerosis.
Consequently, many patients seeking medical cannabis have turned to private specialist clinics, where treatment can involve significant ongoing costs.
Boots' entry into the sector could bring greater public awareness and mainstream recognition to medical cannabis as a specialist treatment option.
However, the service is private, meaning patients should not assume that treatment will be available free of charge through the NHS.
Alongside the launch, Boots has announced that it is exploring a collaborative research programme with the University of Nottingham.
The proposed research will examine patient outcomes, prescribing practices and patient experiences, particularly in the treatment of chronic pain.
The aim is to contribute to the growing body of real-world evidence surrounding cannabis-based medicines and help inform future clinical practice.
Boots Chief Healthcare Officer Jamie Kerruish said the service was designed to give patients another treatment option when conventional approaches had not provided adequate relief.
He said: "Medical cannabis is a specialist area of healthcare and, through SureLeaf, we're giving eligible patients another treatment option to consider, supported by clinical expertise and robust ongoing care."
Boots Online Doctor Medical Director Dr David Gwynne also emphasised the importance of patient safety and clinical oversight.
He said medical cannabis was not appropriate for everyone and that prescribing decisions needed to be made carefully on an individual basis.